



1857 86TH STREET, BROOKLYN NY 11214
TEL: 718-232-1515 | FAX: 718-232-1550

Date: December 20, 2016

Laboratory Update:

Prostate Health Index (PHI)

HIGHLIGHTS


- 3x more specific for prostate cancer than PSA
- The only blood test recommended in the NCCN Guidelines for PCa Early Detection
- A tool to reduce negative biopsies and provide more confidence in your biopsy decision
- A simple, non-invasive blood test



"Committed to Excellence"

Lenco Laboratory is pleased to announce we now offer a newly FDA-approved test, Prostate Health Index (PHI).

PHI utilizes a calculation that combines the results of three quantitative blood serum immunoassays (PSA, free PSA and p2PSA) into a single numerical result (the "*phi* score"). This score gives you more accurate information on what an elevated PSA level might mean and the probability of finding cancer on biopsy.*



BETTER DETECTION TO REDUCE NEGATIVE BIOPSIES

PSA is a widely used screening tool for prostate cancer. However, with PSA's limited specificity, a more precise tool is needed for prostate cancer detection. That tool was found in the discovery of PHI.

The significantly higher specificity of PHI means a greater probability of detecting those patients that actually need a biopsy, allowing for a substantial decrease in the number of prostate biopsies that are reported as negative for cancer.






1857 86TH STREET, BROOKLYN NY 11214
TEL: 718-232-1515 | FAX: 718-232-1550



USING PHI IN YOUR CLINICAL PRACTICE

Because PHI is three times more specific than PSA for detecting prostate cancer, it fills the diagnostic gap between PSA screening and a prostate biopsy. Combined with family and patient history the PHI results can be used to determine the best individualized patient management decisions.



We would like to thank you, our clients, for allowing us to be your preferred laboratory. We are continuously working to provide you and your staff the excellent service and support that clinical services demand. If you have any questions, please call your Lenco Sales/Service Representative or our Client Services Department at 718-232-1515, ext 9.

Best Regards,

A handwritten signature in black ink, appearing to read "E. Agranovsky".

Dr. Elena Agranovsky
Medical Director



1857 86TH STREET, BROOKLYN NY 11214
TEL: 718-232-1515 | FAX: 718-232-1550

TEST NAME:	Prostate Health Index (PHI)
TEST NUMBER:	6700, 72100
COLLECTION:	2 mL serum
CONTAINER:	SST
TRANSPORT/STABILITY:	Refrigerated 24 hours
REJECTION:	Grossly hemolyzed or lipemic specimen
DAYS SET UP:	Monday – Sunday
EXPECTED TAT:	24 hours
METHOD:	Gel Chromatography
CPT CODE(S):	84153, 84154, 86316

* The PHI results are intended to be used as an aid in distinguishing prostate cancer from benign prostatic conditions in men 50 years of age and older with total PSA results in the 4 – 10 ng/mL range and negative digital rectal examination (DRE) findings.